Denosumab effects on serum levels of the bone morphogenetic proteins antagonist noggin in patients with transfusion-dependent thalassemia and osteoporosis

References

• De Sanctis V, Soliman AT, Elsefdy H, et al. Bone disease in β thalassemia patients: past, present and future perspectives. Metab Clin Exp. 2018;80:66–79. DOI:10.1016/j.metabol.2017.09.012. PubMed PMID: 28987275.
   PubMed Web of Science ®Google Scholar
• Baldini M, Forti S, Marcon A, et al. Endocrine and bone disease in appropriately treated adult patients with beta-thalassemia major. Ann Hematol. 2010;89(12):1207–1213. DOI:10.1007/s00277-010-1007-0. PubMed PMID: 20582415.
   PubMed Web of Science ®Google Scholar
• Voskaridou E, Terpos E, Spina G, et al. Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassaemia. Br J Haematol. 2003;123(4):730–737. PubMed PMID: 14616979. doi: 10.1046/j.1365-2141.2003.04657.x
   PubMed Web of Science ®Google Scholar
• Voskaridou E, Anagnostopoulos A, Konstantopoulos K, et al. Zoledronic acid for the treatment of osteoporosis in patients with beta-thalassemia: results from a single-center, randomized, placebo-controlled trial. Haematologica. 2006;91(9):1193–1202. PubMed PMID: 16956818.
   PubMed Web of Science ®Google Scholar
• Voskaridou E, Ntanasis-Stathopoulos I, Papaefstathiou A, et al. Denosumab in transfusion-dependent thalassemia osteoporosis: a randomized, placebo-controlled, double-blind, phase 2b clinical trial. Blood Adv. 2018;2(21):2837–2847. PubMed PMID: 30381400. doi: 10.1182/bloodadvances.2018023085
   PubMed Web of Science ®Google Scholar
• Anastasilakis AD, Toulis KA, Polyzos SA, et al. RANKL inhibition for the management of patients with benign metabolic bone disorders. Expert Opin Investig Drugs. 2009;18(8):1085–1102. DOI:10.1517/13543780903048929. PubMed PMID: 19558335.
   PubMed Web of Science ®Google Scholar
• Papapoulos S, Lippuner K, Roux C, et al. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM extension study. Osteoporos Int. 2015;26(12):2773–2783. DOI:10.1007/s00198-015-3234-7. PubMed PMID: 26202488; PubMed Central PMCID: PMCPMC4656716.
   PubMed Web of Science ®Google Scholar
• Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010;28(35):5132–5139. DOI:10.1200/JCO.2010.29.7101. PubMed PMID: 21060033.
   PubMed Web of Science ®Google Scholar
• Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377(9768):813–822. DOI:10.1016/S0140-6736(10)62344-6. PubMed PMID: 21353695; PubMed Central PMCID: PMCPMC3090685.
   PubMed Web of Science ®Google Scholar
• Raje N, Terpos E, Willenbacher W, et al. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. Lancet Oncol. 2018;19(3):370–381. DOI:10.1016/S1470-2045(18)30072-X. PubMed PMID: 29429912.
   PubMed Web of Science ®Google Scholar
• Voskaridou E, Stoupa E, Antoniadou L, et al. Osteoporosis and osteosclerosis in sickle cell/beta-thalassemia: the role of the RANKL/osteoprotegerin axis. Haematologica. 2006;91(6):813–816. PubMed PMID: 16704959.
   PubMed Web of Science ®Google Scholar
• Krause C, Guzman A, Knaus P. Noggin. Int J Biochem Cell Biol. 2011;43(4):478–481. DOI:10.1016/j.biocel.2011.01.007. PubMed PMID: 21256973.
   PubMed Web of Science ®Google Scholar
• Xie Z, Wang P, Li Y, et al. Imbalance between bone morphogenetic protein 2 and noggin induces abnormal osteogenic differentiation of mesenchymal stem cells in ankylosing spondylitis. Arthritis Rheumatol. 2016;68(2):430–440. DOI:10.1002/art.39433. PubMed PMID: 26413886.
   PubMed Web of Science ®Google Scholar
• Secondini C, Wetterwald A, Schwaninger R, et al. The role of the BMP signaling antagonist noggin in the development of prostate cancer osteolytic bone metastasis. PLoS One. 2011;6(1):e16078. DOI:10.1371/journal.pone.0016078. PubMed PMID: 21249149; PubMed Central PMCID: PMCPMC3020964.
   PubMed Web of Science ®Google Scholar
• Voskaridou E, Christoulas D, Plata E, et al. High circulating sclerostin is present in patients with thalassemia-associated osteoporosis and correlates with bone mineral density. Horm Metab Res. 2012;44(12):909–913. DOI:10.1055/s-0032-1312618. PubMed PMID: 22581647.
   PubMed Web of Science ®Google Scholar
• Voskaridou E, Christoulas D, Xirakia C, et al. Serum dickkopf-1 is increased and correlates with reduced bone mineral density in patients with thalassemia-induced osteoporosis. reduction post-zoledronic acid administration. Haematologica. 2009;94(5):725–728. DOI:10.3324/haema-tol.2008.000893. PubMed PMID: 19407319; PubMed Central PMCID: PMCPMC2675686. doi: 10.3324/haematol.2008.000893
   PubMed Web of Science ®Google Scholar
• Hawa G, Sonnleitner L, Missbichler A, et al. Single step, direct fluorescence immunoassays based on metal enhanced fluorescence (MEF-FIA) applicable as micro plate-, array-, multiplexing- or point of care-format. Anal Biochem. 2018;549:39–44. DOI:10.1016/j.ab.2018.03.002. PubMed PMID: 29518350.
   PubMed Web of Science ®Google Scholar
• Canalis E, Economides AN, Gazzerro E. Bone morphogenetic proteins, their antagonists, and the skeleton. Endocr Rev. 2003;24(2):218–235. DOI:10.1210/er.2002-0023. PubMed PMID: 12700180.
   PubMed Web of Science ®Google Scholar
• Parrow NL, Gardenghi S, Ramos P, et al. Decreased hepcidin expression in murine beta-thalassemia is associated with suppression of Bmp/Smad signaling. Blood. 2012;119(13):3187–3189. DOI:10.1182/blood-2012-01-405563. PubMed PMID: 22461476.
   PubMed Web of Science ®Google Scholar
• Biver E, Hardouin P, Caverzasio J. The “bone morphogenic proteins” pathways in bone and joint diseases: translational perspectives from physiopathology to therapeutic targets. Cytokine Growth Factor Rev. 2013;24(1):69–81. DOI:10.1016/j.cytogfr.2012.06.003. PubMed PMID: 22749766.
   PubMed Web of Science ®Google Scholar
• Bandyopadhyay A, Yadav PS, Prashar P. BMP signaling in development and diseases: a pharmacological perspective. Biochem Pharmacol. 2013;85(7):857–864. DOI:10.1016/j.bcp.2013.01.004. PubMed PMID: 23333766.
   PubMed Web of Science ®Google Scholar
• Gazzerro E, Gangji V, Canalis E. Bone morphogenetic proteins induce the expression of noggin, which limits their activity in cultured rat osteoblasts. J Clin Invest. 1998;102(12):2106–2114. DOI:10.1172/JCI3459. PubMed PMID: 9854046; PubMed Central PMCID: PMCPMC509165.
   PubMed Web of Science ®Google Scholar
• Devlin RD, Du Z, Pereira RC, et al. Skeletal overexpression of noggin results in osteopenia and reduced bone formation. Endocrinology. 2003;144(5):1972–1978. DOI:10.1210/en.2002-220918. PubMed PMID: 12697704.
   PubMed Web of Science ®Google Scholar
• Wu XB, Li Y, Schneider A, et al. Impaired osteoblastic differentiation, reduced bone formation, and severe osteoporosis in noggin-overexpressing mice. J Clin Invest. 2003;112(6):924–934. DOI:10.1172/JCI15543. PubMed PMID: 12975477; PubMed Central PMCID: PMCPMC193662.
   PubMed Web of Science ®Google Scholar
• Moffett SP, Dillon KA, Yerges LM, et al. Identification and association analysis of single nucleotide polymorphisms in the human noggin (NOG) gene and osteoporosis phenotypes. Bone. 2009;44(5):999–1002. DOI:10.1016/j.bone.2008.12.024. PubMed PMID: 19167531.
   PubMed Web of Science ®Google Scholar
• Cheung CL, Lau KS, Sham PC, et al. Genetic variants in GREM2 are associated with bone mineral density in a southern Chinese population. J Clin Endocrinol Metab. 2013;98(9):E1557–E1561. DOI:10.1210/jc.2013-1983. PubMed PMID: 23902946.
   PubMed Web of Science ®Google Scholar
• Kaminski A, Bogacz A, Uzar I, et al. Association betweenGREM2 gene polymorphism with osteoporosis and osteopenia in postmenopausal women. Eur J Obstet Gynecol Reprod Biol. 2018;228:238–242. DOI:10.1016/j.ejogrb.2018.07.009. PubMed PMID: 30014930.
   PubMed Web of Science ®Google Scholar
• Schwaninger R, Rentsch CA, Wetterwald A, et al. Lack of noggin expression by cancer cells is a determinant of the osteoblast response in bone metastases. Am J Pathol. 2007;170(1):160–175. DOI:10.2353/ajpath.2007.051276. PubMed PMID: 17200191; PubMed Central PMCID: PMCPMC1762703.
   PubMed Web of Science ®Google Scholar
• Buijs JT, Petersen M, van der Horst G, et al. Bone morphogenetic proteins and its receptors; therapeutic targets in cancer progression and bone metastasis? Curr Pharm Des. 2010;16(11):1291–1300. PubMed PMID: 20166979. doi: 10.2174/138161210791033987
   PubMed Web of Science ®Google Scholar
• Terpos E, Ntanasis-Stathopoulos I, Gavriatopoulou M, et al. Pathogenesis of bone disease in multiple myeloma: from bench to bedside. Blood Cancer J. 2018;8(1):7. DOI:10.1038/s41408-017-0037-4. PubMed PMID: 29330358; PubMed Central PMCID: PMCPMC5802524.
   PubMed Web of Science ®Google Scholar
• Lowery JW, Rosen V. Bone morphogenetic protein-based therapeutic approaches. Cold Spring Harb Perspect Biol. 2018;10(4):a022327. DOI:10.1101/cshperspect.a022327. PubMed PMID: 28389444.
   PubMed Web of Science ®Google Scholar
• Tsialogiannis E, Polyzois I, Oak Tang Q, et al. Targeting bone morphogenetic protein antagonists: in vitro and in vivo evidence of their role in bone metabolism. Expert Opin Ther Targets. 2009;13(1):123–137. DOI:10.1517/14728220802637725. PubMed PMID: 19063711.
   PubMed Web of Science ®Google Scholar
• Takayama K, Suzuki A, Manaka T, et al. RNA interference for noggin enhances the biological activity of bone morphogenetic proteins in vivo and in vitro. J Bone Miner Metab. 2009;27(4):402–411. DOI:10.1007/s00774-009-0054-x. PubMed PMID: 19252814.
   PubMed Web of Science ®Google Scholar
• Paine-Saunders S, Viviano BL, Economides AN, et al. Heparan sulfate proteoglycans retain noggin at the cell surface: a potential mechanism for shaping bone morphogenetic protein gradients. J Biol Chem. 2002;277(3):2089–2096. DOI:10.1074/jbc.M109151200. PubMed PMID: 11706034.
   PubMed Web of Science ®Google Scholar
• Srinivas TR, Ho B, Kang J, et al. Post hoc analyses: after the facts. Transplantation. 2015;99(1):17–20. DOI:10.1097/TP.0000000000000581. PubMed PMID: 25525920.
   PubMed Web of Science ®Google Scholar
• Seeman E, Delmas PD. Bone quality–the material and structural basis of bone strength and fragility. N Engl J Med. 2006;354(21):2250–2261. DOI:10.1056/NEJMra053077. PubMed PMID: 16723616.
   PubMed Web of Science ®Google Scholar
• Cefalu CA. Is bone mineral density predictive of fracture risk reduction? Curr Med Res Opin. 2004;20(3):341–349. DOI:10.1185/030079903125003062. PubMed PMID: 15025843.
   PubMed Web of Science ®Google Scholar